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Background: It is unclear whether concomitant use of clopidogrel and proton-pump inhibitors (PPIs) increases the
risk of recurrence of cardiovascular disease or death in patients at high risk of upper gastrointestinal (GI) bleeding.
Methods: Based on the Swedish Patient Register, a cohort of cardiovascular disease (including acute myocardial
infarction, stroke and angina, from 2006 to 2008) was selected from a population with any diagnosis of upper GI
bleeding. Data on drug prescription was retrieved from the Prescribed Drug Register. Patients entered into the
cohort after their first discharge for cardiovascular disease and were followed up to death, recurrence of
cardiovascular disease, or 90 days. A Cox regression model was conducted and hazard ratios (HRs) with 95%
confidence intervals (CIs) were estimated to evaluate the risks among users of different drug prescriptions.
Results: Patients who were current users of only PPIs (HR 2.02, 95% CI 1.19-3.44), only clopidogrel (HR 1.14, 95% CI
0.53-2.45) and nonusers of both (HR 2.36, 95% CI 1.39-4.00) were at a higher risk of death compared with patients
with a concomitant use. Results were similar among 1779 patients who had any history of upper GI bleeding
(HR 2.05, 95% CI 1.18-3.54; HR 1.25, 95% CI 0.57-2.72; HR 2.30, 95% CI 1.33-3.98, respectively).
Conclusion: Among patients at high risk of upper GI bleeding, those with a concomitant use of PPIs and
clopidogrel were at a decreased risk of mortality, and possibly also a decreased risk of recurrence of cardiovascular
disease.
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Clopidogrel is a widely used medication for atheros-
clerotic diseases [1], particularly in the prevention of
thrombotic events in stable cardiovascular disease, and
as a secondary prevention after myocardial infarction
and stroke [2,3]. Upper gastrointestinal (GI) bleeding
is, however, a common and potentially serious adverse
event in clopidogrel users [4]. Proton-pump inhibitors
(PPIs), drugs that alleviate acid-related symptoms by
inhibition of the hydrogen-potassium adenosine trip-
hosphatase enzyme in gastric mucosa [5,6], are often
prescribed to prevent such bleedings [5,7-9]. However,* Correspondence: yunxia.lu@ki.se
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reproduction in any medium, provided the orthere are reports of an increased risk of mortality and
recurrence of cardiovascular disease among patients
with concomitant use of clopidogrel and PPIs [10-14]. A
possible mechanism is that PPIs, which are mainly me-
tabolized by the cytochrome system, might counteract
the inhibitory effect of clopidogrel on platelet aggrega-
tion [15,16]. Nevertheless, some other studies have failed
to find any interaction between clopidogrel and PPIs
[17-19], or any increase in the risk of cardiovascular re-
hospitalizations [20]. There is presently no general con-
sensus on this issue, although the US Food and Drug
Administration and the European Medicines Agency
have stated that PPIs may reduce the effect of clopido-
grel in the prevention of serious cardiovascular events
[21,22].
During the past four years, accumulating relevant stu-
dies have been published. Few studies, however, havetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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risk of upper GI bleeding [23]. Most have excluded pa-
tients with a history of GI bleeding [14,17,18,20,24]
although these patients might be at high risk of a recur-
rence of severe GI bleeding. Furthermore, these studies
have mainly evaluated the combined use of clopidogrel
and aspirin together with PPIs which might dilute or
mix the real interaction between clopidogrel and PPIs
[25,26]. In addition, recurrence of cardiovascular disease
is the major measured outcome in most previous studies
rather than death. Death, though, is the most important
and clearly measured outcome for cardiovascular disease
and acute peptic ulcer bleeding. The recurrence of car-
diovascular disease is, however, generally difficult to be
identified completely.
In this cohort study, we focused on cardiovascular dis-
ease with any diagnosis of upper GI bleeding to clarify
whether concomitant use of clopidogrel and PPIs in-
creases the risk of recurrence of cardiovascular disease
or death, compared with other treatment strategies.
Methods
Study design
Within a population-based cohort of patients (1987 to
2008 in Sweden) with any hospitalization for compli-
cated upper GI ulcer disease (International Classification
of Disease 10th revision [ICD] diagnosis codes: K25-K28
with .0 .1 .2 .4 .5 .6), patients were selected for the final
study if they had been hospitalized for cardiovascular
disease from 2006 until the end of 2008. The entry date
into the study cohort was the discharge date of the first
cardiovascular disease hospitalization after January 1, 2006
(Figure 1). Patients were followed for 60, 90, 180 andFigure 1 The flow chart for study design. The timeline showed how the
July 1st, 2005. This study chose to start on January, 1st 2006 thus at least h
discharged from hospitalizations for cardiovascular diseases since January, 1
second cardiovascular event (1), death (2), migration (3), or end of study (4
upper GI bleeding or they bled during/after the follow up period but befo
diseases.360 days to assess the outcomes death, re-hospitalization,
or revisit to outpatient/primary health care for cardiovas-
cular disease. In this study, we only present the results of
the 90-day follow-up. The reason for this is that the short-
term drug prescriptions after discharge for cardiovascular
disease might more appropriately reflect the treatment in
relation to fatality and recurrence. Moreover, restriction of
the follow-up to only 60 days, 180 days and 360 days after
entry rendered similar results to the 90-day follow-up
(data not shown).
Data sources
Data regarding basic patient information (admission
date, discharge date, main diagnosis and secondary diag-
nosis) were retrieved from the Swedish Patient Register,
which has been completed nationwide since 1987. Infor-
mation on prescribed drugs and dates of dispatch were
retrieved from the similarly complete Swedish Pre-
scribed Drug Register (SPDR), which was initiated in
July 1, 2005. This register contains information on age,
sex, personal number, prescriber's profession and prac-
tice and, particularly, drug utilization and expenditure
on prescribed drugs for the entire Swedish population.
The defined cohort began on January 1, 2006, in order
to ensure drug exposure covering at least half a year.
The legally compulsory register of prescribed drugs in
Sweden guarantees the complete capture of drugs ex-
posure in this study. Death dates and underlying causes
of death were identified from the nationwide complete
Swedish Cause of Death Register (initiated in 1952), and
data on cancer as a co-morbidity was collected from the
nationwide complete Swedish Cancer Register (initiated
in 1958).cohort was defined. The Swedish Prescribed Drug Register started on
alf-year drug exposure information can be guaranteed. Patients who
st 2006 were included in the cohort. They had been followed up the
) within 90 days follow-up period. All of the patients had historical
re December, 31, 2008. Symbol ⊕ means diagnosis of cardiovascular
Wang et al. BMC Pharmacology and Toxicology 2014, 15:22 Page 3 of 8
http://www.biomedcentral.com/2050-6511/15/22Identification of the study cohort
As we described above in the Study design section, pa-
tients with a first hospitalization for cardiovascular disease
(including acute myocardial infarction, stroke, and angina)
after January 1, 2006, were included in the study. These
diseases were identified from the following ICD codes:
main diagnosis or co-diagnosis of acute myocardial infarc-
tion (I21, I22), main diagnosis or co-diagnosis of ischemic
stroke (I63, I64), and main diagnosis of angina (I20). In
order to focus on clopidogrel and PPIs, we excluded pa-
tients with any filled prescription of aspirin (Anatomical
Therapeutic Chemical [ATC] code: B01AC06, N02BA01,
A01AD05) during the study period. Patients were also ex-
cluded from the final study cohort if they had previous
acute myocardial infarction, stroke or angina hospitaliza-
tions within one year before entry, if they had emigrated
before January 1, 2006, or if they had a cardiovascular re-
hospitalization or had died less than 7 days after entry.
Drug exposures
Current drug use was categorized into four groups: i)
only PPIs, ii) only clopidogrel, iii) both clopidogrel and
PPIs and, iv) no PPIs or clopidogrel. All the PPI types
available in Sweden were included (omeprazole, pan-
toprazole, lansoprazole, rabeprazole, esomeprazole). The
sample size did not allow separate analyses of single PPI
groups. We calculated drug exposures at 30 days before
the entry date as some patients might have had leftovers
of previous PPIs or clopidogrel prescriptions at hand,
which might have met their demands for current medi-
cations. We also analyzed the data using drug exposure
that started from the entry date, or drug exposure 60
days before the entry. All of the results based on three
definitions of exposures were similar. Thus, to make the
study more concise, we only used the first definition of
drug exposure. In Sweden, the typical prescription for
PPIs or clopidogrel is for approximately 90 days or less.
The extra 30 days plus 90 days of follow-up ensured
enough time to cover any defined drug exposures. The
ATC codes for clopidogrel were B01AC04 and B01AC30,
and the ATC codes for PPIs were A02BC01-05 and
A02BD01-06.
Definition of outcomes
The outcomes under study were: recurrence of acute
myocardial infarction (main or secondary diagnosis
codes I21 or I22), stroke (main or secondary diagnosis
codes I60-I64), angina (main diagnosis code I20), or all-
cause mortality. We also specified hemorrhagic stroke
and ischemic stroke from the total stroke patients.
Co-morbidities
A co-morbidity score was calculated based on the fol-
lowing concomitant diagnoses: i) chronic heart failure(diagnosis code I50); ii) diabetes (diagnosis codes E10-
E14); iii) chronic liver insufficiency (diagnosis codes K702-
K704, K709, K717, K72, or K743-K746); iv) chronic renal
insufficiency (diagnosis codes N18, N19, I132, I200, or
I311); v) chronic obstructive lung disease (diagnosis codes
J42-J44); vi) malignancy (diagnosis codes C00-C97). The
reason for the selection of these diseases for the calcula-
tion of the co-morbidity score is because they are very
commonly diagnosed and are composed of the most fre-
quent causes of death in an elderly population [27,28].
The number of co-morbidities was categorized into four
groups: no concomitant diagnosis, one concomitant diag-
nosis, two concomitant diagnoses, three or more con-
comitant diagnoses. History of cardiovascular disease was
defined as any diagnosis of acute myocardial infarction,
stroke, or angina at least one year before entry into the
study cohort.
Statistical analyses
A proportional risk model was conducted and hazard
ratios (HRs) with 95% confidence intervals (CI) were es-
timated to evaluate the risk of death or cardiovascular
disease in users of different categories of drug prescrip-
tions. Current clopidogrel and PPI prescriptions were set
as the reference. Patients who were diagnosed as having
acute myocardial infarction at entry were analyzed as a
subgroup and compared with patients diagnosed as hav-
ing overall cardiovascular disease including acute myo-
cardial infarction. Analyses were specified for patients
who had a hospitalization for upper GI bleeding before
or after the cardiovascular disease hospitalizations. The
characteristics of patients for the diagnosis of upper GI
bleeding were categorized into four groups based on a
bleeding episode which happened before, during or after
the study period. Group I contained patients who had a
history of peptic ulcer bleeding before cohort entry.
Group II contained patients who had a bleeding history
and who bled again during the study period. Group III
contained patients who had no history of bleeding but
experienced a bleeding episode during the study period,
and Group IV contained patients who did not bleed dur-
ing but after the defined study period. Compared with
the general population, all these patients are apt to have
a higher risk of GI bleeding, therefore, reasonable sub-
jects for analysis in a whole group [29,30]. Furthermore,
we performed additional analysis for sub-groups. Since
there are a limited number of patients in the third and
fourth groups, we only did a sub-analysis for patients
who had a history of upper GI bleeding (Groups I and
II). All of the proportional models were adjusted for age
(<65, 65–74, 75–84, ≥85), sex (male, female), history of
cardiovascular disease (yes, no), history of bleeding (yes,
no), and co-morbidity (0, 1, 2, 3 or more). To assess sur-
veillance bias, additional analyses were conducted after
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(the Statistical Analysis System, version 9.2, SAS Insti-
tute Inc., Cary, NC, USA) was used for all analyses. The




In total, 98 725 cases of peptic ulcer bleeding were





Men 1227 55% 3
Women 992 45% 3
Age group, years
<65 291 13% 5
65-75 425 19% 9
75-85 844 38% 2
> = 85 659 30% 2
Upper gastrointestinal bleeding
I. Bleeding before entry 1730 78% 5
II. Bleeding before entry and during the follow up 49 2% 2
III. New bleeding during the follow up period 86 4% 4
IV. Bleeding after endpoints 354 16% 9
Cardiovascular disease history
No 1315 59% 4
Yes 904 41% 2
Comorbidities (number)
0 1382 62% 3
1 628 28% 2
2 173 8% 8
≥3 36 2% 2
Drug exposure
Current clopidogrel and PPIs§ 309 14% 9
No current PPIs or clopidogrel 861 39% 2
Current only PPIs 847 38% 3
Current only clopidogrel 202 9% 5
Patients with diagnosis of bleeding before entry
Current clopidogrel and PPIs 252 14% 7
No current PPIs or clopidogrel 659 37% 1
Current only PPIs 714 40% 2
Current only clopidogrel 154 9% 3
subtotal 1779 5
*CVD cardiovascular disease; **AMI acute myocardial infarction; §PPIs proton-pumpthem, 2285 first cardiovascular disease events were in-
cluded in the study. Table 1 shows the baseline character-
istics of the study participants at the time of inclusion.
Among the patients with cardiovascular disease, we also
did a sub-group analysis for acute myocardial infarction
(Tables 1 and 2). The cohorts were followed for the out-
comes death and recurrence of cardiovascular disease. Of
the 2285 cardiovascular disease patients, 1536 (67%) were
older than 75 years of age and 1269 (56%) were men.
There were 812 (36%) current users of only PPIs, 165 (7%)ardiovascular disease
Re-hospitalization for cardiovascular disease
MI** cohort CVD* cohort AMI** cohort
umber (%) Number (%) Number (%)
73 2285 695
65 54% 1269 56% 374 54%
08 46% 1016 44% 321 46%
7 8% 303 13% 62 9%
5 14% 446 20% 98 14%
80 42% 872 38% 292 42%
41 36% 664 29% 243 35%
13 76% 1773 78% 527 76%
2 3% 44 2% 20 3%
1 6% 71 3% 33 5%
7 14% 397 17% 115 17%
56 68% 1361 60% 475 68%
17 32% 924 40% 220 32%
28 49% 1426 62% 340 49%
44 36% 643 28% 250 36%
1 12% 178 8% 85 12%
0 3% 38 2% 20 3%
5 14% 403 18% 116 17%
11 31% 905 40% 226 33%
16 47% 812 36% 308 44%
1 8% 165 7% 45 6%
8 15% 244 13% 77 14%
54 29% 702 39% 164 30%
65 50% 713 39% 266 49%
8 7% 158 9% 40 7%
35 1817 547
inhibitors.
Table 2 Risk of death or recurrent cardiovascular events in 90 days follow-up among cardiovascular disease patients
Drug exposures Cardiovascular disease cohort Acute myocardial infarction cohort
Death Cardiovascular disease Death Cardiovascular disease
§HR (95% CI) §HR (95% CI) §HR (95% CI ) §HR (95% CI)
Total cohort
Current clopodogrel and PPI** (reference) 1.00 1.00 1.00 1.00
No PPI and no clopidogrel 2.36 (1.39-4.00) 1.54 (1.05-2.24) 3.13 (1.47-6.68) 1.77 (0.92-3.41)
Current only PPIs 2.02 (1.19-3.44) 1.11 (0.75-1.65) 1.93 (0.91-4.11) 1.02 (0.52-1.99)
Current only clopidogrel 1.14 (0.53-2.45) 1.80 (1.15-2.83) 1.88 (0.70-5.03) 1.88 (0.85-4.08)
Patients with diagnosis of bleeding before entry*
Current clopodogrel and PPI(reference) 1.00 1.00 1.00 1.00
No PPI and no clopidogrel 2.30 (1.33-3.98) 1.54 (0.98-2.40) 3.30 (1.47-7.41) 1.65 (0.78-3.47)
Current only PPI 2.05 (1.18-3.54) 1.04 (0.65-1.65) 2.12 (0.95-4.73) 0.80 (0.37-1.72)
Current only clopidogrel 1.25 (0.57-2.72) 1.84 (1.07-3.16) 2.26 (0.82-6.26) 1.78 (0.70-4.57)
*cohort members had history of upper gastrointestinal bleeding before entry into the cohorts. Results for patients who had any other hospitalizations for upper
gastrointestinal bleeding were not shown due to the small number of cases.
**PPIs proton-pump inhibitors.
§HR harzard ratio; CI confidence interval. All of the proportional models were adjusted for age (<65, 65–74, 75–84, ≥85), sex (male, female), history of
cardiovascular diseases (yes, no), history of bleeding (yes, no), and co-morbidity (0, 1, 2, 3 or more).
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users of concomitant prescriptions of PPIs and clopido-
grel. In patients who only used one type of PPI, there were
878 omeprazole users, 162 esomeprazole users, 96 lanso-
prazole, 95 pantoprazole and 5 rabeprazole users. Among
all participants, 245 (11%) died within the 90-day follow-
up, 158 (7%) suffered ischemic stroke and 8 (0.3%) he-
morrhagic stroke, while among 1817 (80%) patients with a
diagnosis of upper GI bleeding before first entry into the
cardiovascular disease cohort, 225 (13%) died within
90 days after discharge.
Hazard ratios for different drug exposures in the
cardiovascular disease cohort
The HR for risk of death within 90 days of follow-up
was 2.02 (95% CI 1.19-3.44) for current users of only
PPIs, 1.14 (95% CI 0.53-2.45) for current users of only
clopidogrel, and 2.36 (95% CI 1.39-4.00) among pa-
tients with no PPI or clopidogrel prescription, compared
with patients using PPIs and clopidogrel concomitantly
(Table 2). Regarding the risk of recurrent cardiovascular
disease, the corresponding HRs were: 1.11 (95% CI 0.75-
1.65), 1.80 (95% CI 1.15-2.83), and 1.54 (95% CI 1.05-
2.24), respectively.
Hazard ratios for different drug exposures in the acute
myocardial infarction cohort
In the acute myocardial infarction cohort, the HR for
risk of death was 1.93 (95% 0.91-4.11) for current users
of only PPIs, 1.88 (95% 0.70-5.03) for current users of
only clopidogrel, and 3.13 (95% CI 1.47-6.68) for pa-
tients with no PPI or clopidogrel prescriptions. All theHRs for the risk of recurrent cardiovascular disease after
acute myocardial infarction are not statistically diffe-
rent when compared to concomitant use of PPIs and
clopidogrel.
Patients with a diagnosis of upper GI bleeding before
entry
Patients with any upper GI bleeding diagnosis before
entry into the study were analyzed separately. The re-
sults were consistent with the main analyses (Table 2).
An elevated risk of death (HR 2.05, 95% 1.18-3.54) was
detected for current only PPIs, and an increased risk of
recurrent cardiovascular disease (HR 1.84, 95% CI 1.07-
3.16) was found for current use of only clopidogrel, com-
pared with concomitant use of PPIs and clopidogrel.
Restricting the cohort to those who had experienced
a bleeding within one year before entry rendered similar
results (data not shown).
Discussion and conclusions
This study reveals no evidence of an increased risk of
death or recurrence of cardiovascular disease among con-
comitant users of clopidogrel and PPIs in a population
with a high risk of upper GI bleeding. Use of clopidogrel
or PPIs alone seems to increase the risk of mortality and
recurrent cardiovascular disease compared with concomi-
tant use of these drugs.
Strengths of the study include the large sample size
and the data collection from registers with complete na-
tionwide coverage of the drug exposures and outcomes,
i.e., recurrent cardiovascular disease and death. The na-
tionwide register-based design counteracts selection and
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ding patients with any recorded prescription of aspirin.
There are, however, also several weaknesses. Filled pre-
scriptions of PPIs and clopidogrel were regarded as the ex-
posure, but there was no information on whether the
patients had actually taken their medications. Also, PPI
sub-types could not be analyzed separately due to the lim-
ited number, although the safety of pantoprazole has been
specifically targeted in some studies [31]. More studies
with a large sample size for possibly separating the ana-
lysis of PPI subtypes are warranted. In addition, it was not
possible to entirely distinguish patients with a filled pre-
scription after hospital admission from patients who still
had drugs left from prescriptions filled before the index
admission. Furthermore, we had no data on some import-
ant risk factors at baseline, such as tobacco smoking and
alcohol consumption, which may bias the results [32]. We
were, however, able to control for cardiovascular history
and other co-morbidity as registered on hospital admis-
sion. Finally, confounding by indication could not be
avoided completely in this observational study. Reasons
for patients lacking any prescriptions might indicate that
some completely recovered or that they might have had
such severe symptoms that their physicians decided
not to use any medication. These two opposite statu-
ses of patients might make the confounding by indi-
cation less influential. The reason why some patients
had only prescriptions of clopidogrel or only PPIs might
be due to the recent reports of the increased risk of con-
comitant use of these two drugs rather than any specific
disease indications. On the other hand, the consistently
increased risk of recurrence of cardiovascular disease in
clopidogrel only patients compared with the concomitant
users may indicate the competing risk of death in this
group.
Whether concomitant prescriptions of clopidogrel PPIs
are associated with an increased recurrence of cardiovas-
cular events is controversial [33]. Some studies have indi-
cated a concern that the interaction between clopidogrel
and PPIs could impair the treatment effect of clopidogrel
[10-14,16], but others have not found any association. In-
stead, an independent cardiovascular risk by PPIs alone
has been detected in a few studies. Several relevant meta-
analyses have been published since 2010. Hulot and his
coworkers initiated a meta-analysis in 2009 focusing
on clopidogrel-treated patients with cytochrome P450
2C19*2 loss-of-function allele or the co-administration of
PPIs. The results displayed an increased risk of major ad-
verse cardiovascular events in the co-administration of
clopidogrel and PPIs [34]. During the same year, the study
by Kwok et al. showed that propensity-matched or ran-
domized trial participants had no associated cardiovascu-
lar risk with PPIs, whereas other observational studies
generally showed a significant association [35]. The sameteam published an updated study in 2012 with a focus on
the potential risk with individual PPIs. They found an
elevated risk of PPI therapy alone is associated with
an adverse cardiovascular risk. They also admitted that
major adverse cardiovascular events were mostly lim-
ited by the moderate to substantial heterogeneity of
the studies included for meta-analysis. The high pos-
sibility of confounding and bias was indicated [31].
Siller-Matula and his colleagues published another meta-
analysis in 2010. Their results indicated that concomi-
tant PPI use might be associated with an increased
risk of cardiovascular events but does not influence the
risk of death. Articles included in these meta-analyses
were not completely the same due to different inclusion
criteria and time of publication. They further confirmed
the presence of significant heterogeneity which might in-
dicate that the evidence is biased, confounded, or in-
consistent [36]. The clinical validity or relevance of the
hypothesized PPI-clopidogrel interaction, thus, remains
questionable.
The present study indicates that the co-administration
of clopidogrel and PPIs results in a better effect regard-
ing the prevention of death in patients with a high risk
of GI bleeding. The current findings are consistent with
some previous studies [17-20,37-40]. For example, a co-
hort study in the US and Canada which included 18 565
patients with acute coronary syndrome undergoing percu-
taneous coronary intervention (PCI) found no conclusive
evidence of a clopidogrel-PPI interaction, even though
there was a slightly increased risk of hospitalization for
myocardial infarction. A study from Austria included 300
patients with coronary artery disease who had PCI. The
platelet reactivity index was measured in patients with
and without PPIs, and no interaction was found between
clopidogrel and pantoprazole or esomeprazole [17]. One
big cohort study from Denmark found that the apparent
association between recurrent myocardial infarction and
the use of PPIs with clopidogrel is affected by confounding
by indication. The association is not present when con-
founding is addressed by design [41]. Although indications
of reduced antiplatelet activity have been found in vivo in
the case of PPI administration in clopidogrel users, the
interaction between antiplatelet agents and PPIs at the
enzymatic level does not seem to result in worse clinical
outcomes.
In summary, recent studies have shown conflicting
and inconsistent data regarding the adverse interaction
of clopidogrel and PPIs. Together with our study, we
think clinicians should focus on the potential harm from
ulcers or hemorrhage before deciding to omit PPIs in
patients taking clopidogrel. In selected patients at high-
risk of GI bleeding, clinicians should in fact be very cau-
tious and cannot overlook the life-threatening risk that
bleedings represent.
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